Role of topical beta blockers in regression of infantile capillary hemangioma

Abstract

Objective: To observe efficacy of Timolol maleate 0.5% by topical and surface application in infantile superficial capillary hemangioma of eyelid.
 Methods: This multi-centered clinical case series was carried out at Ophthalmology Department of Bilawal Medical College and Institute of Ophthalmology, LUMHS, Jamshoro from November 2019 to May 2020. We included 14 subjects. All the patients were subjected to detailed clinical examination. Before starting the topical beta blockers, the enrolled subjects had obtained the expert opinion by pediatrician to rule out any preexisting developmental cardio vascular disease. Topical beta blockers 0.5% drops were thus started with, against the ongoing finding of superficial capillary hemangioma of eyelid.
 Results: There was significant regression in size of infantile hemangioma after treating with topical timolol maleate 0.5%. We included 14 subjects in this study. Mean±SD age of patients was 4.94. Complete regression was seen in 08 subjects at the end of 12 weeks (64%) while 03 were completely cured at 08 weeks (21%) and 01 patient lost follow up with us. No significant ocular and systemic side effects were noted.
 Conclusion: Topical timolol maleate 0.5% can be the first-line treatment modality for superficial capillary hemangiomas due to its better safety and efficacy.
 doi: https://doi.org/10.12669/pjms.37.7.4317
 How to cite this:Junejo MS, Rebecca, Memon MN, Shaikh SP. Role of topical beta blockers in regression of infantile capillary hemangioma. Pak J Med Sci. 2021;37(7):---------. doi: https://doi.org/10.12669/pjms.37.7.4317
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Avaliação in vivo da segurança de tartarato de metoprolol intravítreo em olhos com hemangioma circunscrito de coroide. Estudo fase I

“…Após o primeiro relato de hemangioma infantil palpebral tratado com timolol tópico em 2010 Ni, 2010), diversos estudos (Ni et al, 2011;Calvo et al, 2013;Püttgen et al 2016;Junejo et al 2021), incluindo uma revisão sistemática (Ovadia et al, 2015) e meta análise (Wang et al, 2021) descreveram resultados com perfil de efeito adverso favorável. As concentrações de maleato de timolol utilizadas variaram entre 0,1%, 0,25% e 0,5% (maioria dos estudos) e com posologia de 12 em 12 horas Ni, 2010;Ni et al, 2011;Calvo et al, 2013).…”